North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
Purified Mouse Anti-Human Disialoganglioside GD2 14.G2a RUO

Purified Mouse Anti-Human Disialoganglioside GD2 

Clone  14.G2a   (RUO)

  • Brand BD Pharmingen™
  • Alternative Name GD2; Disialoganglioside GD2; Ganglioside GD2
  • Concentration 0.5 mg/ml
  • Isotype Mouse BALB/c IgG2a
  • Reactivity Human (QC Testing)  Mouse (Tested in Development) 
  • Application Flow cytometry (Routinely Tested) 
    Immunohistochemistry-frozen, Cytotoxicity, Immunofluorescence (Reported) 
  • Immunogen LAN-1 human neuroblastoma cells
  • Storage Buffer Aqueous buffered solution containing ≤0.09% sodium azide.
  • Regulatory Status RUO
Product Details Recommended Assay References

Description

Gangliosides are sialic-acid bearing glycolipids that are expressed on the surface of all mammalian cells, and are likely involved in mediating cell-substratum interactions. They are important target antigens for antibody dependent cellular cytotoxicity (ADCC) of human melanoma and neuroblastoma cells. Human melanoma cells produce gangliosides, designated as GD2 and GD3 which are deposited in the subtratum-attached material, and may play a significant role in the melanoma metastatic phenotype. Clone 14.G2a specifically reacts with human and mouse GD2 ganglioside. LAN-1 human neuroblastoma cells were used as immunogen. Clone 14.G2a is an isotype switch variant selected from the parental IgG3-producing hybridoma 14.18 and has identical reactivity as the parental antibody. Clone 14.G2a is routinely tested by flow cytometry using M21 human melanoma cells.

Format
  • Format Purified

Other Formats →

Suggested Companion Products

Stain Buffer (FBS) RUO
500 mL Cat No: 554656

Purified Mouse IgG2a, κ Isotype Control RUO
0.1 mg Cat No: 556651

PE Goat Anti-Mouse Ig (Multiple Adsorption) Polyclonal RUO
0.2 mg Cat No: 550589

FITC Goat Anti-Mouse IgG/IgM Polyclonal RUO
0.5 mg Cat No: 555988

Resources & Tools
 Spectrum Viewer  Download TDS
Preparation and Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  6. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.


Human neuroblastoma and melanoma cells are suggested as positive controls. Clone 14.G2a has also been reported for antibody-dependent and complement-mediated cytotoxicity of GD2 positive tumor cells and inhibit the growth of GD2 positive cells in athymic nude mice.


  1. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci U S A. 1985; 82(15):5155-5159. View reference

  2. Cheresh DA, Klier FG. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin. J Cell Biol. 1986; 102(5):1887-1897. View reference

  3. Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986; 102(3):688-696. View reference

  4. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 1986; 46(10):5112-5118. View reference

  5. Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997; 80(2):317-333. View reference

  6. Hakomori S. Tumor-associated carbohydrate antigens. Annu Rev Immunol. 1984; 2:103-126. View reference

  7. Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 1998; 58(14):2925-2928. View reference

  8. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987; 47(4):1098-1104. View reference

  9. Mujoo K, Kipps TJ, Yang HM, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989; 49(11):2857-2861. View reference

554272 Rev. 11
Instruments
Reagents
Applications
Sales & Support
BD BioSciences